You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023401
Nov 2023230059
Dec 20235908
Jan 20243203
Feb 20245208
Mar 2024116016
Apr 2024132012
May 202414805
Jun 2024145011
Jul 2024194019
Aug 202492015
Sep 2024189015
Oct 2024532024
Nov 2024300029
Dec 2024166013
Jan 2025185016
Feb 202586025
Mar 20250032
Apr 20250021
May 20250013
Jun 2025107
Total26630352